Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change +0.17
Percentage change 1.92	%

Peers: REGN ALNY VRTX NBIX BMRN IONS SAGE RARE AGIO BLUE

| Held by: IWM VTI VXF IWN IWO VTWO XPH VHT IWC ITOT

Index	RUT	P/E	-	EPS (ttm)	-2.41	Insider Own	13.08%	Shs Outstand	68.81M	Perf Week	1.01%
Market Cap	621.37M	Forward P/E	-	EPS next Y	-2.91	Insider Trans	0.22%	Shs Float	59.81M	Perf Month	64.63%
Income	-146.78M	PEG	-	EPS next Q	-0.81	Inst Own	96.94%	Short Float	11.98%	Perf Quarter	38.50%
Sales	56.04M	P/S	11.09	EPS this Y	-28.05%	Inst Trans	-0.97%	Short Ratio	8.64	Perf Half Y	6.74%
Book/sh	4.34	P/B	2.08	EPS next Y	2.11%	ROA	-42.43%	Short Interest	7.17M	Perf Year	-4.14%
Cash/sh	4.62	P/C	1.95	EPS next 5Y	0.51%	ROE	-53.54%	52W Range	3.91 - 13.98	Perf YTD	21.21%
Dividend Est.	-	P/FCF	-	EPS past 5Y	15.65%	ROIC	-45.77%	52W High	-35.43%	Beta	1.65
Dividend TTM	-	Quick Ratio	7.79	Sales past 5Y	16.27%	Gross Margin	93.29%	52W Low	130.95%	ATR (14)	0.56
Dividend Ex-Date	-	Current Ratio	7.85	EPS Y/Y TTM	-31.81%	Oper. Margin	-287.94%	RSI (14)	72.64	Volatility	3.31% 5.11%
Employees	165	Debt/Eq	0.08	Sales Y/Y TTM	12.04%	Profit Margin	-261.91%	Recom	1.08	Target Price	32.00
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-17.06%	Payout	-	Rel Volume	0.99	Prev Close	8.86
Sales Surprise	210.52%	EPS Surprise	3.47%	Sales Q/Q	109.29%	Earnings	May 07 BMO	Avg Volume	829.90K	Price	9.03
SMA20	21.36%	SMA50	38.80%	SMA200	16.12%	Trades		Volume	822,443	Change	1.92%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-25	Initiated	Citigroup	Buy	$33
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-22-24	Initiated	JP Morgan	Overweight	$35
Nov-02-23	Initiated	Mizuho	Buy	$20
Apr-21-23	Initiated	Robert W. Baird	Outperform	$33
Jul-07-22	Initiated	Chardan Capital Markets	Buy	$21
Mar-01-21	Initiated	Cowen	Outperform	$25
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight	$22
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral	$4 → $1
Nov-04-19	Resumed	Laidlaw	Buy	$5
Sep-12-19	Initiated	Guggenheim	Buy

Show Previous Ratings

Jun-06-25 11:54AM	Breakout Momentum Plays You May Not Know About (MarketBeat) +8.36%
May-28-25 04:01PM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +18.12%
May-27-25 07:00AM	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
May-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +7.17%
May-13-25 07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
02:49PM	Loading…
May-07-25 02:49PM	Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum (Seeking Alpha)
02:49PM	EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:22AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Apr-30-25 07:00AM	EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-25 07:00AM	EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference (GlobeNewswire)
Mar-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
02:14AM	Loading…
Mar-06-25 02:14AM	Q4 2024 EyePoint Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	EyePoint Pharmaceuticals Inc (EYPT) Q4 2024 Earnings Call Highlights: Navigating Challenges ... (GuruFocus.com)
Mar-05-25 09:30AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks) +8.22%
08:25AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:34AM	EyePoint Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Reports Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-04-25 07:17AM	Earnings To Watch: EyePoint Pharmaceuticals Inc (EYPT) Reports Q4 2024 Result (GuruFocus.com) +6.29%
07:00AM	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Feb-26-25 07:00AM	EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025 (GlobeNewswire)
Feb-25-25 07:00AM	EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-17-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-05-25 07:00AM	EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema Meeting Primary and Secondary Endpoints (GlobeNewswire)
Jan-30-25 07:00AM	EyePoint to Present at Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-16-25 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.46%
Jan-13-25 07:00AM	EyePoint Provides Company Update and Anticipated Development Milestones for 2025 (GlobeNewswire) -7.07%
07:00AM	Loading…
Jan-08-25 07:00AM	EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors (GlobeNewswire)
Dec-17-24 07:25AM	EyePoint reports inducement grants under NASDAQ listing rule (TipRanks) +5.39%
07:00AM	EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 07:06AM	EyePoint doses first patient in second Phase 3 LUCIA clinical trial (TipRanks)
Dec-04-24 07:00AM	EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Nov-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.43%
Nov-13-24 09:55AM	Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High? (Zacks)
Nov-12-24 06:45AM	EyePoint price target lowered to $33 from $38 at Baird (TipRanks) -7.42%
Nov-07-24 08:35AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:37AM	EyePoint Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-04-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Oct-31-24 04:00PM	EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
Oct-29-24 09:47PM	EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering (GlobeNewswire)
04:49AM	EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock? (Zacks)
Oct-28-24 05:14PM	EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire) +27.58%
12:16PM	EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss (Benzinga)
07:00AM	EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema (GlobeNewswire)
Oct-24-24 07:00AM	EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire)
Oct-23-24 09:20AM	ANI Pharmaceuticals price target raised to $62 from $60 at Truist (TipRanks) -7.35%
Oct-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +14.17%
Sep-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 07:00AM	EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors (GlobeNewswire)
Aug-27-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Aug-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 07:00AM	EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.90%
Aug-07-24 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:09AM	EyePoint Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Jul-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-24 08:00AM	Milestone Pharmaceuticals Refreshes Board of Directors (GlobeNewswire)
Jun-26-24 08:00AM	EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 (GlobeNewswire)
08:00AM	EyePoint Pharmaceuticals to Highlight DURAVYU (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 (GlobeNewswire)
Jun-18-24 07:00AM	EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 (GlobeNewswire)
Jun-17-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 07:00AM	EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire) +6.18%
02:35AM	Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) (GuruFocus.com)
May-17-24 02:34AM	Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT) (GuruFocus.com) -5.43%
May-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-24 02:34PM	EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges (GuruFocus.com)
May-08-24 01:54PM	EYPT Stock Earnings: EyePoint Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:48AM	Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating (MT Newswires)
07:23AM	EyePoint Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
May-07-24 09:32AM	Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating (MT Newswires) +5.98%
May-06-24 11:00AM	Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday? (Benzinga) -43.26%
08:42AM	EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint (MT Newswires)
07:00AM	EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU in Non-Proliferative Diabetic Retinopathy (GlobeNewswire)
Apr-23-24 01:21PM	Hedge Fund and Insider Trading News: David Tepper, Ray Dalio, RA Capital Management, Millennium Management, Biohaven Ltd (BHVN), EyePoint Pharmaceuticals Inc. (EYPT), and More (Insider Monkey)
Apr-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 07:00AM	EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists (GlobeNewswire)
Mar-18-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-15-24 01:00PM	5 Growth Stocks Under $50 for March 2024 (Investopedia)
Mar-08-24 09:31AM	EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 09:39PM	Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:25PM	EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023 (GuruFocus.com)
12:53PM	EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
09:30AM	Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics (Zacks)
07:20AM	EyePoint Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Mar-04-24 07:00AM	EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire) -7.46%
Feb-29-24 10:00AM	Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know (Zacks)
08:50AM	Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going (Zacks)
07:00AM	EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 (GlobeNewswire)
04:19AM	20 Countries With Worst Vision Problems (Insider Monkey)
Feb-27-24 07:00AM	EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire) +7.98%
Feb-16-24 07:00AM	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-15-24 12:00PM	Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice (Zacks)
Feb-13-24 09:55AM	Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet (Zacks)

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elston George	Chief Financial Officer	May 25 '25	Option Exercise	0.00	7,500	0	83,050	May 27 04:08 PM
Zaderej Karen L.	Director	May 19 '25	Buy	5.99	5,000	29,950	36,500	May 19 04:06 PM
Zaderej Karen L.	Director	May 16 '25	Buy	5.81	5,000	29,050	31,500	May 19 04:06 PM
Zaderej Karen L.	Director	May 15 '25	Buy	5.47	5,000	27,350	26,500	May 15 04:06 PM
Zaderej Karen L.	Director	May 14 '25	Buy	5.42	5,000	27,100	21,500	May 15 04:06 PM
Elston George	Chief Financial Officer	Feb 09 '25	Option Exercise	0.00	5,834	0	75,550	Feb 11 06:19 PM
Lurker Nancy	Director	Feb 09 '25	Option Exercise	0.00	20,000	0	205,436	Feb 11 06:19 PM
Duker Jay S.	President and CEO	Feb 09 '25	Option Exercise	0.00	7,000	0	79,706	Feb 11 06:19 PM
Elston George	Chief Financial Officer	Jan 06 '25	Option Exercise	0.00	15,285	0	73,374	Jan 07 04:04 PM
Elston George	Chief Financial Officer	Jan 05 '25	Option Exercise	0.00	15,000	0	63,356	Jan 07 04:04 PM
Lurker Nancy	Director	Jan 06 '25	Option Exercise	0.00	75,134	0	185,436	Jan 07 04:04 PM
Lurker Nancy	Director	Jan 05 '25	Option Exercise	0.00	12,667	0	110,302	Jan 07 04:04 PM
Landis John B.	Director	Jan 05 '25	Option Exercise	0.00	10,000	0	21,400	Jan 07 04:04 PM
Duker Jay S.	President and CEO	Jan 06 '25	Option Exercise	0.00	20,794	0	78,814	Jan 07 04:03 PM
Duker Jay S.	President and CEO	Jan 05 '25	Option Exercise	0.00	30,000	0	68,027	Jan 07 04:03 PM
ANTHONY P. ADAMIS	Director	Oct 23 '24	Proposed Sale	10.04	67,100	673,355		Oct 23 04:34 PM
David R. Guyer	Former Director	Oct 14 '24	Proposed Sale	8.92	36,975	329,817		Oct 15 11:58 AM
DICICCO WENDY F	Director	Aug 20 '24	Buy	7.79	2,567	19,997	9,967	Aug 21 04:32 PM
ANDO GORAN	Director	Aug 21 '24	Buy	7.95	5,000	39,750	13,150	Aug 21 04:01 PM
Zaderej Karen L.	Director	Aug 19 '24	Buy	7.98	12,500	99,750	16,500	Aug 21 04:01 PM
Lurker Nancy	Director	Aug 16 '24	Buy	7.88	3,173	25,003	97,635	Aug 20 04:04 PM
GUYER DAVID R	Director	Jul 12 '24	Option Exercise	3.34	9,775	32,646	13,475	Jul 16 04:24 PM
GUYER DAVID R	Director	Jul 12 '24	Sale	10.06	11,625	116,995	1,850	Jul 16 04:24 PM
Duker Jay S.	President and CEO	Jul 10 '24	Option Exercise	0.00	16,666	0	46,086	Jul 12 05:04 PM
Lurker Nancy	Executive Vice Chair	Jul 10 '24	Option Exercise	0.00	11,111	0	94,462	Jul 12 05:03 PM
Zaderej Karen L.	Director	Jul 11 '24	Option Exercise	0.00	2,000	0	4,000	Jul 12 05:00 PM
ADAMIS ANTHONY P	Director	Jun 23 '24	Option Exercise	0.00	2,000	0	4,000	Jun 25 04:16 PM

Open in Screener

AXGN

Axogen Inc

Jun 13 • 04:00PM ET

9.75

Dollar change -0.29
Percentage change -2.89	%

Healthcare • Medical Devices • USA • NASD

Peers: IART BAX SYK ZBH MDT JNJ GMED EW PODD HOLX

| Held by: VTI VXF IWM IWO VTWO IHI FESM SCHA DWAS PTH

Index	RUT	P/E	-	EPS (ttm)	-0.16	Insider Own	5.63%	Shs Outstand	45.51M	Perf Week	-10.71%
Market Cap	444.05M	Forward P/E	20.53	EPS next Y	0.47	Insider Trans	-3.54%	Shs Float	43.02M	Perf Month	-17.51%
Income	-7.16M	PEG	-	EPS next Q	0.06	Inst Own	86.27%	Short Float	4.76%	Perf Quarter	-43.48%
Sales	194.52M	P/S	2.28	EPS this Y	60.71%	Inst Trans	8.86%	Short Ratio	3.53	Perf Half Y	-34.30%
Book/sh	2.32	P/B	4.21	EPS next Y	127.35%	ROA	-3.74%	Short Interest	2.05M	Perf Year	32.11%
Cash/sh	0.62	P/C	15.82	EPS next 5Y	86.26%	ROE	-7.22%	52W Range	6.59 - 21.00	Perf YTD	-40.84%
Dividend Est.	-	P/FCF	373.15	EPS past 5Y	21.24%	ROIC	-4.17%	52W High	-53.57%	Beta	1.05
Dividend TTM	-	Quick Ratio	2.65	Sales past 5Y	11.91%	Gross Margin	74.18%	52W Low	47.95%	ATR (14)	0.64
Dividend Ex-Date	Jan 27, 2010	Current Ratio	4.28	EPS Y/Y TTM	67.41%	Oper. Margin	-0.25%	RSI (14)	27.37	Volatility	3.16% 2.46%
Employees	452	Debt/Eq	0.65	Sales Y/Y TTM	18.81%	Profit Margin	-3.68%	Recom	1.12	Target Price	24.25
Option/Short	Yes / Yes	LT Debt/Eq	0.63	EPS Q/Q	44.76%	Payout	-	Rel Volume	0.96	Prev Close	10.04
Sales Surprise	0.53%	EPS Surprise	-236.99%	Sales Q/Q	17.36%	Earnings	May 08 BMO	Avg Volume	580.55K	Price	9.75
SMA20	-10.80%	SMA50	-27.93%	SMA200	-35.60%	Trades		Volume	559,281	Change	-2.89%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-25	Initiated	Lake Street	Buy	$30
Jul-01-24	Initiated	Raymond James	Outperform	$13
Nov-11-22	Resumed	Jefferies	Buy	$15
May-09-22	Upgrade	Canaccord Genuity	Hold → Buy	$10 → $15
Mar-11-22	Resumed	Cantor Fitzgerald	Overweight	$21
Oct-23-20	Initiated	Guggenheim	Buy	$24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$16
May-07-20	Downgrade	Canaccord Genuity	Buy → Hold	$12
Apr-02-20	Downgrade	BTIG Research	Buy → Neutral
Aug-07-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-12-19	Initiated	Canaccord Genuity	Buy	$32
Mar-02-18	Reiterated	Lake Street	Buy	$26 → $38
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Nov-30-17	Initiated	Jefferies	Buy	$35
Nov-21-17	Reiterated	Lake Street	Buy	$22 → $26
Jul-31-17	Initiated	Leerink Partners	Outperform	$22
Jun-30-17	Initiated	Cantor Fitzgerald	Overweight	$18
Mar-06-17	Initiated	ROTH Capital	Buy	$14.50
Nov-22-16	Upgrade	Lake Street	Hold → Buy	$9 → $11
Nov-07-16	Reiterated	Wedbush	Outperform	$10 → $12

Show Previous Ratings

May-28-25 08:00AM	Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-21-25 09:35AM	AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-09-25 09:45AM	Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline (Zacks) -9.73%
09:30AM	MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off (Zacks)
03:08AM	Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ... (GuruFocus.com)
08:30AM	Loading…
May-08-25 08:30AM	AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -23.18%
07:28AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Reports 2025 First Quarter Financial Results (GlobeNewswire)
07:00AM	Axogen Announces Chief Financial Officer Transition (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
01:09PM	COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised (Zacks)
12:31PM	AxoGen Q1 2025 Earnings Preview (Seeking Alpha)
May-02-25 01:22PM	SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View (Zacks)
01:21PM	DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins (Zacks)
Apr-24-25 08:04AM	Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025 (GlobeNewswire)
03:03PM	Loading…
Mar-31-25 03:03PM	Stryker Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Mar-25-25 11:12AM	Axogen: LT Bullish, But Outcomes Weighted To Downside, At This Point (SeekingAlpha)
Mar-24-25 08:00AM	Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-25 03:04PM	Alcon Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Feb-26-25 02:03AM	Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ... (GuruFocus.com)
12:27AM	Q4 2024 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:41AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance) +11.66%
07:10AM	Axogen, Inc. To Host Analyst & Investor Day on March 4th (GlobeNewswire)
07:00AM	Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-11-25 04:58PM	Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 (GlobeNewswire)
Feb-03-25 08:00AM	Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 09:35AM	AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? (Zacks)
05:05AM	AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? (Zacks)
Jan-10-25 05:00PM	Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.21%
08:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024 (GlobeNewswire)
09:15AM	Loading…
Dec-24-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks) -5.41%
Dec-19-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-28-24 12:00PM	All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy (Zacks)
Nov-25-24 09:55AM	How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% (Zacks)
Nov-08-24 07:35AM	AxoGen Reports Strong Q3 2024 Revenue Growth (TipRanks)
02:08AM	Axogen Inc (AXGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-07-24 07:48AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance) -13.44%
07:00AM	Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update (GlobeNewswire)
Oct-24-24 07:00AM	Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 (GlobeNewswire)
Oct-14-24 07:21AM	AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Oct-09-24 05:30PM	Axogen Inc (AXGN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Sep-12-24 01:30AM	ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc (GuruFocus.com)
Sep-06-24 07:00AM	Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft (GlobeNewswire)
Sep-04-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-03-24 07:00AM	Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-30-24 12:00PM	What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-23-24 09:55AM	Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? (Zacks)
Aug-19-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-13-24 04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-09-24 12:56AM	Axogen names ex-Abbott exec Michael Dale as CEO (MedTech Dive)
Aug-08-24 08:20AM	AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates (Zacks) +35.10%
07:19AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Announces New Leadership Appointments (GlobeNewswire)
07:00AM	Axogen, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.06%
Jul-23-24 07:00AM	Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 (GlobeNewswire)
Jul-12-24 08:37AM	AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks)
Jul-01-24 07:00AM	Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.49%
Jun-25-24 12:52PM	AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection (Zacks)
Jun-24-24 07:00AM	Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix (GlobeNewswire)
Jun-12-24 04:56AM	Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength? (Zacks) +9.21%
May-28-24 04:30PM	Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia (GlobeNewswire) +5.90%
May-17-24 12:29PM	AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft (Zacks)
May-16-24 02:56PM	AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft (MT Newswires)
07:00AM	Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft (GlobeNewswire)
May-14-24 07:00AM	Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference (GlobeNewswire)
May-06-24 10:31AM	AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:02AM	Axogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
May-02-24 11:57AM	AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -10.37%
08:15AM	AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:14AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 04:50PM	Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix (GlobeNewswire)
Apr-16-24 07:00AM	Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 (GlobeNewswire)
Mar-08-24 11:55PM	Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN) (GuruFocus.com)
Mar-06-24 08:20AM	AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-05-24 09:27PM	Q4 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) -15.11%
11:53AM	AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:38AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Axogen Inc (AXGN) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full-Year 2023 (GuruFocus.com)
07:00AM	Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-28-24 08:50AM	AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Feb-26-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Feb-13-24 04:30PM	Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024 (GlobeNewswire)
Feb-12-24 08:50AM	Here's Why Momentum in AxoGen (AXGN) Should Keep going (Zacks)
Feb-06-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-02-24 04:15PM	Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-26-24 08:50AM	Here's What Could Help AxoGen (AXGN) Maintain Its Recent Price Strength (Zacks)
Jan-18-24 05:00PM	Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap (GlobeNewswire) +7.86%
Jan-04-24 04:45PM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023 (GlobeNewswire) +26.67%
04:40PM	Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025 (GlobeNewswire)
04:35PM	Axogen Announces Promotions on Research and Development Team (GlobeNewswire)
Dec-26-23 04:15PM	Axogen, Inc. Appoints Kathy Weiler to its Board of Directors (GlobeNewswire)
Dec-06-23 07:00AM	Axogen Announces Transition of Finance Team Leadership (GlobeNewswire) +5.19%
Dec-01-23 05:00PM	Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.04%
Nov-20-23 07:00AM	Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-08-23 09:41AM	AxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 11:01PM	Q3 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) +36.90%
08:04AM	Axogen Inc (AXGN) Reports 12% Revenue Growth in Q3 2023 (GuruFocus.com)
07:15AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance)

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weiler Kathy Johnson	Director	Jun 09 '25	Sale	10.61	4,073	43,215	6,580	Jun 11 04:27 PM
Levine Alan M	Director	Jun 09 '25	Sale	10.61	4,073	43,215	36,743	Jun 11 04:26 PM
Wendell Amy McBride	Director	Jun 09 '25	Sale	10.61	4,073	43,215	93,826	Jun 11 04:26 PM
Burke William P. Mr.	Director	Jun 09 '25	Sale	10.61	4,073	43,215	24,484	Jun 11 04:25 PM
NEELS GUIDO J	Director	Jun 09 '25	Sale	10.61	4,073	43,215	86,743	Jun 11 04:24 PM
JOHNSON JOHN	Director	Jun 09 '25	Sale	10.61	4,073	43,215	24,943	Jun 11 04:23 PM
TYNDALL JOSEPH A.	Director	Jun 10 '25	Option Exercise	6.56	11,586	75,952	26,931	Jun 11 04:22 PM
TYNDALL JOSEPH A.	Director	Jun 10 '25	Sale	10.72	26,931	288,700	0	Jun 11 04:22 PM
JOSEPH A TYNDALL	Director	Jun 10 '25	Proposed Sale	10.72	26,931	288,814		Jun 10 05:41 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Option Exercise	6.30	12,850	80,955	35,407	May 23 04:32 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Sale	11.20	20,062	224,694	15,345	May 23 04:32 PM
TYNDALL JOSEPH A.	Director	May 19 '25	Sale	11.63	2,525	29,366	22,557	May 23 04:12 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Proposed Sale	11.15	32,339	360,580		May 22 05:14 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '25	Option Exercise	0.00	32,462	0	232,873	Mar 19 05:24 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 19 '25	Sale	17.50	15,111	264,442	217,762	Mar 19 05:24 PM
Began Marc A	EVP & General Counsel	Mar 01 '25	Option Exercise	0.00	22,500	0	24,186	Mar 05 06:24 PM
Wendell Amy McBride	Director	Mar 03 '25	Sale	20.02	5,000	100,100	97,899	Mar 05 06:20 PM
DeVinney Erick Wayne	Chief Innovation Officer	Feb 28 '25	Option Exercise	0.00	24,799	0	209,301	Mar 04 07:22 PM
AMY MCBRIDE-WENDELL	Director	Mar 03 '25	Proposed Sale	20.01	5,000	100,050		Mar 03 04:16 PM
Kemp Jens	Chief Marketing Officer	Feb 22 '25	Option Exercise	0.00	2,500	0	2,500	Feb 26 04:25 PM
Zaderej Karen L.	SENIOR ADVISOR	Jan 21 '25	Proposed Sale	18.41	220,000	4,050,000		Jan 21 01:20 PM
Zaderej Karen L.	SENIOR ADVISOR	Jan 14 '25	Proposed Sale	18.00	100,000	1,800,000		Jan 14 01:24 PM
Zaderej Karen L.	SENIOR ADVISOR	Nov 07 '24	Proposed Sale	12.71	70,000	890,000		Nov 07 10:52 AM
Zaderej Karen L.	SENIOR ADVISOR	Sep 05 '24	Proposed Sale	13.00	150,000	1,950,000		Sep 05 04:33 PM
JOHNSON JOHN	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	29,016	Sep 04 09:13 PM
NEELS GUIDO J	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	90,816	Sep 04 09:11 PM
Levine Alan M	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	40,816	Sep 04 08:58 PM
Burke William P. Mr.	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	28,557	Sep 04 08:52 PM
THOMAS PAUL	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	32,052	Sep 04 08:33 PM
TYNDALL JOSEPH A.	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	22,557	Sep 04 07:52 PM
Wendell Amy McBride	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	102,899	Sep 04 05:18 PM
Donovan Michael Patrick	Officer	Aug 21 '24	Proposed Sale	12.42	28,003	347,810		Aug 21 04:31 PM
GREG FREITAG	Director	Aug 13 '24	Proposed Sale	11.17	15,000	167,520		Aug 13 05:00 PM
Zaderej Karen L.	SENIOR ADVISOR	Aug 12 '24	Proposed Sale	10.00	200,000	2,000,000		Aug 12 10:59 AM

EYPT

EyePoint Pharmaceuticals Inc

AXGN

Axogen Inc

Upgrade your FINVIZ experience